Schizophrenia Clinical Trials in Phoenix

Showing 21-40 of 124 trials

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.

Schizophrenia

Reviva Pharmaceuticals690 participantsStarted Jan 2022

Phoenix, Arizona, United States • Bentonville, Arkansas, United States • Little Rock, Arkansas, United States +15 more locations

COMPLETEDPhase 3256 miles

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

NCT04959032

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).

Schizophrenia

Intra-Cellular Therapies, Inc.228 participantsStarted Jul 2021

Little Rock, Arkansas, United States • Bellflower, California, United States • Cerritos, California, United States +40 more locations

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Schizophrenia Trials in Other Cities

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

Relapse Prevention Study in Patients With Schizophrenia

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Relative Bioavailability of LY03010 Compared to Listed Drug

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Improving Cognition Via Exercise in Schizophrenia

Other Conditions in Phoenix